Pfizer's strong architecture adjustment, "fat enterprise" must finally "slim down"

Read: Pfizer moves to remove the "Coos" position!According to the drug intelligence network learned that the insider sifted that Pfizer announced three departments to report directly to the president of Greater ChinaCase1: Pfizerin Pfizer's structure, we have removed the position of Chief Operating Officer and replaced it with the business unit reporting directly to the President of Greater ChinaThe three business units are: hospital sales, retail, and innovative Internet health servicesCase2: NovartisNovartis Pharmaceuticals announces to employees that from June 1, Novartis's sales team will set up three regional sales directors in Beijing, Shanghai and Guangzhou to report directly to Thomas Rowland, head of the immunization, liver, pico and respiratory divisionsThe head of the national sales and market access strategy will leave Novartis to pursue external career development opportunitiesCase3: Internet companieslast year, announced a growing number of companies announcing staff restructuring, in early 2019 did announce 15 percent of layoffs, JD.com last eliminated more than 10 percent of the vice-president-level executives, the United States, Mobai, Know and other Internet companies have also laid off staffmany cases show that enterprises have actively adjusted the organizational structure, the phenomenon of layoffs is not uncommon, its appearance is seemingly to save labor costs, but the essence of the pursuit of enterprise flattened development, the aim is to make enterprises faster, more efficient, thereby directly enhance competitivenessLast year, Oracle China announced 900 job cuts, with netizens joking: "Zhongguancun's largest nursing home has fallen." "In the past, pharmaceutical companies continued to grow, but now the pharmaceutical profits, pharmaceutical "fat enterprises" are slimming down"fat enterprises" must finally "slim down"by the past decade and so on policy and demographic dividends, the pharmaceutical industry is developing rapidly, while the internal extensive management is covered by the false impression of performancemultinational pharmaceutical companies have adopted people-to-people tactics, expand the sales force, regardless of cost and return on investment, once the head of several pharmaceutical companies sales staff peak edpering to more than 5000 peopleA foreign enterprise respiratory products Beijing Hospital set AB gang, monthly sales of 100-200 boxesthe large organization of pharmaceutical companies is not only a problem of efficiency, but also a series of "corporate diseases" (1) "Big business disease" this kind of enterprise is manifested as bloated organizational structure, redundant personnel, too many organizational levels, internal bureaucratization, leading to the organization efficiency is becoming less and less (2) "small company organization" many small companies, blind pursuit of specialization, resulting in the internal professional division of labor too fine, resulting in a serious division of responsibilities, serious departmental barriers When these companies encounter external pressure, they often experience problems and even create an existential crisis whether it is "big business disease", or "small company organization" are disease, there is no disease, the long-term enterprise will be sick Pfizer has the genes of the world's leading pharmaceutical companies, in today's pharmaceutical industry, Pfizer's frequent restructuring, what are the commercial implications behind? First Step: November 2018 Step 2: September 2019 Step 3: June 2020 .1.Road to Jane - Business unit needs to be simplified
from Pfizer's architecture, the business unit consists of three parts, hospital sales, retail, innovative Internet health care business business unit portfolio is more streamlined, especially for generic or generic pharmaceutical companies In the past, most pharmaceutical companies were structured according to the treatment field, each of which was headed by the general manager, emphasizing refinement and specialization The division of labor between departments is very detailed, the division of responsibilities is seriously divided, resulting in high departmental barriers, can not effectively cooperate, forming a "department wall." in today's uncertain era, pharmaceutical companies need to simplify business processes and modules, promote the formation of flexible and borderless organization, the result is that the enterprise business unit is simple, flexible organization, rapid response This business unit is more adaptable to the changing medical policy and the complex medical situation 2." Digital Healthcare "will be the future of business
all pharmaceutical companies are focusing on new business, digital marketing, medical, research and development (1) Sanofi executives were laid off, leaving the chief digital officer four Ofanofi executives to leave in April, reducing the number of executive committees reporting to the CEO from 14 to 10 CDO's position as chief digital officer remains, and its job is to continue to focus on businesses such as digital therapy (2) Innovative Internet Healthcare has become one of the three major businesses of Puqiang
and Pfizer's adjustment, innovative Internet medical services business has become one of the main business units, and is also strengthening the status of digital medical China's vast digital gene population is driving changes in consumption patterns The digital business in the medical field is greatly influenced by the policy, and the digital medicine has not yet formed the scale, but with the aging of the digital gene population, the digital medicine business has gradually become mainstream before that, multinationals have the most sensitive sense of smell the three advantages to lay a flat position
(1) faster the flattening of large enterprises, shorten the feedback decision-making process, accelerate the enterprise's feedback speed in the competition, to bring customers a better experience Last week, the management of a joint venture pharmaceutical company visited a director of Peking University Hospital, medicine, market, regional market, sales line of seven or eight people, hoping to participate in the director's academic program, the director of the introduction of 1 hour, and finally told the director also need to go back to discuss (2) more efficient
flat ness makes communication more concise, and therefore increases efficiency The enterprise structure is very complex, the chief operating officer, the general manager of the business, the general manager of North and South China, the regional manager, the regional manager, the representative, the CEO down 8 floors The most common problem with this architecture is the "shake pot" (3) lower cost there is no doubt that the results are the most reflected in the reduction of corporate labor costs, which is also in line with the needs of all Chinese pharmaceutical companies today summary in an uncertain time, pharmaceutical enterprises want to adapt to China's severe policy environment, the organization of slimming is imminent How to make "fat enterprises" orderly "slim", is not too late, very testing the wisdom of entrepreneurs medical thin profits, is not "thin" and "not thin" problem, but "life" and "death" of the problem, Pfizer "slim" inspiration, worthy of entrepreneurs to think deeply